  The consequences of once-weekly rifapentine plus isoniazid for 3 months ( 3HP) against latent tuberculosis<disease> infections in hemodialysis patients have not been studied before. This is the first study to evaluate the safety and tolerability of 3HP in this population and revealed a completion rate of 65.4 %. The therapy was not associated with hepatotoxicity , but with high rates of adverse events ( 69.2 %).